NutriStem® hPSC XF Medium

Defined, xeno-free, serum-free medium
Designed for optimal growth and expansion of human iPS and hES cells
Name SKU Size Price Qty
NutriStem® hPSC XF Medium 05-100-1A 500 mL
$240.00
  • Buy 6 for $215.00 each and save 11%
  • Buy 9 for $210.00 each and save 13%
NutriStem® hPSC XF Medium 05-100-1B 100 mL
$65.00
NutriStem® hPSC XF Medium (Modified, GF-free, bFGF-free) 06-5100-01-1A 500 mL
$215.00

Description

Details

Product Overview

NutriStem® hPSC XF Medium is a widely published, defined, xeno-free, serum-free cell culture medium designed to support the growth and expansion of human induced pluripotent stem (hiPS) and human embryonic stem (hES) cells. Protocols have been established around the world for applications ranging from derivation to differentiation. NutriStem® hPSC XF Medium offers the ability to culture cells in a completely xeno-free medium without the need for high levels of basic FGF and other stimulatory growth factors and cytokines. In addition, superior cell attachment and proliferation is observed with NutriStem® hPSC XF Medium aid high-throughput screening applications. NutriStem® hPSC XF Medium exhibits a consistent media performance and predictable cellular behavior derived from a defined xeno-free formulation as well as increased reproducibility shown in long-term growth of over 50 passages.

Low-protein formulation that contains stable L-alanyl-L-glutamine and HSA.

NutriStem® hPSC XF Features

  • Defined, serum-free, and xeno-free 
  • Flexible and compatible with multiple matrices
  • Amenable to weekend-free culture
  • FDA Drug Master File (DMF) available, produced under cGMP
  • Enables efficient expansion and growth of hES and hiPS cells in feeder-free culture systems
  • Extensively tested and widely used on multiple hES and iPS cell lines, including H1, H9.2, I6, I3.2, and CL1
hESC were cultured in NutriStem® hPSC XF


Figure: 1 Human Embryonic Stem Cells (H1, passage 6) were seeded in 96-well plates (Matrigel coated) in BI's NutriStem® hPSC XF and competitor's media. Stem cell media were changed every 24 hours. Number of cells was determined using CyQuant™ cell proliferation assay kit.

Sample Data

Cell morphology

hiPS & hESC Normal Colony Morphology on NutriStem medium.

Figure: Normal Colony Morphology. H1 hES cells (top panel) and ACS-1014 hiPS cells (bottom panel) cultured in NutriStem® hPSC XF Medium on Matrigel-coated plates display colony morphologies typical of normal feeder-free hES and hiPS cell cultures, including a uniform colony of tightly compacted cells and distinct colony edges.

Immunostaining

Figure: H1 cell morphology and immunofluorescence analysis of hESC markers red SSEA-4, green OCT4 and blue DAPI. H1 cells stained positive for the expression of pluripotency markers.

Embryoid body formation

Figure: Embryoid bodies (EBs) were generated from H9.2 hES cells cultured for 16 passages in NutriStem® hPSC XF Medium on Matrigel matrix as an evaluation of pluripotency. The pluripotent H9.2 cells were suspended in serum-supplemented medium, where they spontaneously formed EBs containing cells of embryonic germ layers. The following cell types were identified by examination of the histological sections of 14-day-old EBs stained with H&E: (A) neural rosette (ectoderm), (B) neural rosette stained with Tubulin, (C) primitive blood vessels (mesoderm), and (D) megakaryocytes (mesoderm).

Taratoma formation

Figure: H9.2 hES cells were cultured for 11 passages in NutriStem® hPSC XF Medium using a human foreskin fibroblast (HFF) feeder layer. The hES cells were subsequently injected into the hind leg muscle of SCID-beige mice for in vitro evaluation of pluripotency. The following tissues from all three germ layers were identified in H&E-stained histological sections of the teratoma 12 weeks post-injection: (A) cartilage (mesoderm), (B) epithelium (endoderm), and (C) neural rosette (ectoderm).

Specifications

Specifications

Form Liquid
Brand NutriStem®
Storage Conditions Store at -20ºC
Shipping Conditions Dry Ice
Quality Control NutriStem® hPSC is routinely tested for optimal maintenance and expansion of undifferentiated hESCs. Additional standard evaluations are pH, osmolality, endotoxins and sterility tests.
Instructions for Use
  • Upon thawing, the medium may be stored at 2 - 8ºC for 10 to 14 days

  • Media should be aliquotted into smaller working volumes to avoid repeated freeze/thaw cycles 

  • Avoid exposure to light

 

Note: A common feeder-free basement membrane matrix is Matrigel, which is not xeno-free. Effective xeno-free alternatives to Matrigel is recombinant laminin, such as LaminStem(R) 521 (BI Cat. No. 05-753-1F) which has been validated to successfully culture human ES and iPS cells using NutriStem® hPSC XF medium.

Legal NutriStem® hPSC XF is registered as an In-vitro diagnostic (IVD) medical device. NutriStem® is a registered trademark of Biological Industries​.

A Drug Master File (DMF) for NutriStem® hPSC XF is available.

References

references

    Growing Methods of hESC and iPSC (Derivation, Expansion, Scaling up, and Suspensions)

  1. O.M. Russell et al. Preferential amplification of a human mitochondrial DNA deletion in vitro and in vivo. Scientific Reports, volume 8, Article number: 1799 (2018)
  2. J. Rosati et al. Production and characterization of human induced pluripotent stem cells (iPSCs) from Joubert Syndrome: CSSi001-A (2850). Stem Cell Research, Volume 27, March 2018, Pages 74–77
  3. Maroof M Adil, David V Schaffer. Expansion of human pluripotent stem cells. Current Opinion in Chemical Engineering 2017, 15:24–35
  4. Tateno, H. et al. Development of a practical sandwich assay to detect human pluripotent stem cells using cell culture media Regenerative Therapy, Volume 6, June 2017, Pages 1–8
  5. Baker, D. et al. Detecting Genetic Mosaicism in Cultures of Human Pluripotent Stem Cells Stem Cell Reports, 2016
  6. Vega-Crespo, A., et al. Investigating the functionality of an OCT4-short response element in human induced pluripotent stem cells. Molecular Therapy — Methods & Clinical Development 3, Article number: 16050 (2016)
  7. Y.Y. Lipsitz, P.W. Zandstra, Human pluripotent stem cell process parameter optimization in a small scale suspensionbioreactor. BMC Proceedings, 9(Suppl 9), O10, 2015
  8. S. Gregory et al. Autophagic response to cell culture stress in pluripotent stem cells. Biochemical and Biophysical Research Communications, doi:10.1016/j.bbrc.2015.09.080, 2015
  9. N. Desai, P Rambhia and A. Gishto, Human embryonic stem cell cultivation: historical perspective and evolutionof xeno-free culture systems. Reproductive Biology and Endocrinology 13.1 (2015): 9.
  10. T. Yokobori et al., Intestinal epithelial culture under an air-liquid interface: a tool for studying human and mouse esophagi. Diseases of the Esophagus, doi: 10.1111/dote.12346. 2015
  11. L. Healy, L Ruban, Derivation of Induced Pluripotent Stem Cells, Atlas of Human Pluripotent Stem Cells in Culture, pp 149-165. Springer US 2015
  12. W. Siqin et al. Spider silk for xeno-free long-term self-renewal and differentiation of human pluripotent stem cells. Biomaterials 35.30 (2014): 8496-8502.
  13. G. Finesilver, M. Kahana, E. Mitrani. Kidney-Specific Micro-Scaffolds and Kidney Derived Serum FreeConditioned Media support in vitro Expansion, Differentiation, and Organization of Human Embryonic Stem Cells. Tissue Engineering Part C: Methods. -Not available-, ahead of print. doi:10.1089/ten.TEC.2013.0574.
  14. M. Amit, J. Itskovitz-Eldor. Atlas of Human Pluripotent Stem Cells: Derivation and Culturing. Stem Cell Biology and Regenerative Medicine, 2012
  15. R. Bergström, Xeno-free culture of human pluripotent stem cells, Methods Mol Biol. 2011;767:125-36
  16. J.Collins et al,. Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells withSynthetic Modified mRNA. Cell Stem Cell 7 (5): 618-630 (2010).
  17. K. Jacobs et al. Higher-Density Culture in Human Embryonic Stem Cells Results in DNA Damage and GenomeInstability. Stem Cell Reports: 6(3), pp 330–341, 2016


  18. Differentiation of Pluripotent Stem Cells

  19. K.M. Gray et al. Self-oligomerization regulates stability of Survival Motor Neuron (SMN) protein isoforms by sequestering an SCFSlmb degron. Molecular Biology of the Cell, 2017 mbc.E17-11-0627
  20. D.C. Wilkinson et. al. Development of a Three-Dimensional Bioengineering Technology to Generate Lung Tissue for Personalized Disease Modeling. Stem cells translational medicine, 6(2), 2017
  21. E. Welby et al. Isolation and Comparative Transcriptome Analysis of Human Fetal and iPSC-Derived Cone Photoreceptor Cells. Stem Cell Reports (2017), https://doi.org/10.1016/j.stemcr.2017.10.018
  22. R. De-Santis et. al. FUS Mutant Human Motoneurons Display Altered Transcriptome and microRNA Pathways with Implications for ALS Pathogenesis. Stem Cell Reports (2017), https://doi.org/10.1016/j.stemcr.2017.09.004
  23. R.A. Hazim et al. Differentiation of RPE cells from integration-free iPS cells and their cell biological characterization. Stem Cell Research & Therapy 2017
  24. S. Petrus-Reurer et al. Integration of Subretinal Suspension Transplants of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in a Large-Eyed Model of Geographic Atrophy. Retinal Cell Biology, February 2017
  25. X. Yuan et al. A hypomorphic PIGA gene mutation causes severe defects in neuron development and susceptibility to complement-mediated toxicity in a human iPSC model, PLOS ONE, 2017
  26. Lenzi, J., et al. Differentiation of control and ALS mutant human iPSCs into functional skeletal muscle cells, a tool for the study of neuromuscolar diseases. Stem Cell Research: Volume 17, Issue 1, Pages 140–147, 2016.
  27. K. Alessandri et. al. A 3D printed microfluidic device for production of functionalized hydrogel microcapsules forculture and differentiation of human Neuronal Stem Cells (hNSC). Lab on a Chip: 16(9), 2016
  28. D. Voulgaris, Evaluation of Small Molecules for Neuroectoderm differentiation & patterning using Factorial Experimental Design. Master Thesis in Applied Physics, Department of Physics, Division of Biological Physics, Chalmers University of Technology, Göteborg, Sweden 2016
  29. P. Bergström et al. Amyloid precursor protein expression and processing are differentially regulated during cortical neuron differentiation, Scientific Reports, 2016
  30. Tieng, V. ae al. Elimination of proliferating cells from CNS grafts using a Ki67 promoter-driven thymidine kinase, Molecular Therapy — Methods & Clinical Development 6, Article number: 16069, 2016
  31. Brykczynska, U, et al. CGG Repeat-Induced FMR1 Silencing Depends on the Expansion Size in Human iPSCs and Neurons Carrying Unmethylated Full Mutations Stem Cell Reports, 2016
  32. Sellgren ,C.M. et al. Patient-specific models of microglia-mediated engulfment of synapses and neural progenitors Molecular Psychiatry, 2016
  33. Cosset, E. et al. Human tissue engineering allows the identification of active miRNA regulators of glioblastoma aggressiveness Biomaterials, 2016
  34. M. Di Salvio et al. Pur-alpha functionally interacts with FUS carrying ALS-associated mutations. Cell Death & Disease, 2015
  35. A. Reyes, et al. Xeno-Free and Defined Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells Functionally Integrate in a Large-Eyed Preclinical Model Plaza. Stem Cell Reports: Volume 6, Issue 1, p9–17, 2015
  36. Tieng, V. et al.Engineering of Midbrain Organoids Containing Long-Lived Dopaminergic Neurons. Stem Cells and Development. February 2014, 23(13): 1535-1547.
  37. A. J. Schwab, A.D. Ebert, Sensory Neurons Do Not Induce Motor Neuron Loss in a Human Stem Cell Model of SpinalMuscular Atrophy. PLoS One. 2014; 9(7): e103112
  38. H.X. Nguyen et al., Induction of early neural precursors and derivation of tripotent neural stem cells from humanpluripotent stem cells under xeno-free conditions. Journal of Comparative Neurology: Volume 522, Issue 12, pp 2767–2783, 2014
  39. A. Kurtz, A. Bosio, and S. Knoebel. Highly efficient differentiation of hPSC into hepatocyte-like cellsby selection of CXCR4 (CD184) definitive endoderm (DE) cells


  40. Cardiomyocyte differentiation

  41. R. Ophir et al. Inflammation And Contractility Are Altered By Obstructive Sleep Apnea Children's Serum, In Human Embryonic Stem Cell Derived Cardiomyocytes. American Journal of Respiratory and Critical Care Medicine 2017
  42. J. Kristensson, Optimization of Growth Conditions for Expansion of Cardiac Stem Cells Resident in the Adult Human Heart. Master’s thesis in Biotechnology, Department of Physics, Division of Biological Physics, Chalmers University of Technology, Gothenburg, Sweden 2016
  43. S. Rajasingh et al. Generation of Functional Cardiomyocytes fro Efficiently Generated Human iPSCs and a Novel Method of Measuring Contractility. PloS one 10.8, 2015: e0134093
  44. L. Jacquet et al. Three Huntington’s Disease Specific Mutation-Carrying Human Embryonic Stem Cell Lines Have Stable Number of CAG Repeats upon In Vitro Differentiation into Cardiomyocytes. PloS one 10.5, 2015
  45. V. Bellamy et al., Long-term functional benefits of human embryonic stem cell-derived cardiac progenitors embedded into a fibrin scaffold, The Journal of Heart and Lung Transplantation, 2014, in press
  46. E. Di Pasquale et al. Generation of human cardiomyocytes: a differentiation protocol for feeder-free human induced pluripotent stem cells. JoVE (Journal of Visualized Experiments) 76 (2013): e50429-e50429
  47. P.W. Burridge and E.T Zambidis. Highly efficient directed differentiation of human induced pluripotent stem cells into cardiomyocytes. Pluripotent Stem Cells: Methods and Protocols. Methods in Molecular Biology, volume 997, pp 149-161, Humana Press, 2013.


  48. Gene Editing

  49. Sweeney, CL et al.Targeted Repair of CYBB in X-CGD iPSCs Requires Retention of Intronic Sequences for Expression and Functional Correction,Molecular Therapy, 2017
  50. J. Lenzi et al., ALS mutant FUS proteins are recruited into stress granules in induced Pluripotent Stem Cells (iPSCs) derived motoneurons. Disease Models & Mechanisms: 8, 755-766, 2015
  51. T. Cerbini et al., Transfection, Selection, and Colony-picking of Human Induced Pluripotent Stem Cells TALEN-targetedwith a GFP Gene into the AAVS1 Safe Harbor, JoVE (Journal of Visualized Experiments), 2015


  52. Different Basement Matrices

  53. Y Qin, et al. Laminins and cancer stem cells: partners in crime? Seminars in Cancer Biology, 2016
  54. S. Wu et al. Efficient passage of human pluripotent stem cells on spider silk matrices under xeno-free conditions. Cellular and Molecular Life Sciences: 73(7):1479-88, 2015
  55. O. Simonson. Use of Genes and Cells in Regenerative Medicine. Karolinska Institutet, 2015
  56. Nacalai USA Inc. Vitronectin-398™ (Xeno-free). Nacalai USA website
  57. S. Rodin et al., Monolayer culturing and cloning of human pluripotent stem cells on laminin-521–based matrices under xeno-free and chemically defined conditions. Nature Protocols 9, 2354–2368 (2014) doi:10.1038/ nprot.2014.159
  58. Rodin S, et al. Clonal culturing of human embryonic stem cells on laminin-521/E-cadherin matrix in defined and xeno-free environment. Nat Commun. 5:3195. doi: 10.1038/ncomms4195, 2014
  59. StemAdhere™ Defined Matrix for hPSC. Primorigen Biosciences website.
  60. I. lenz et al., Automated 3D Culture to Undifferentiated hESC. (Scientific Poster)
  61. J.L. Weber et al,. The Corning® Synthemax™ Surface: A Synthetic, Xeno-Free Surface for Long-Term Self-Renewal of Human Embryonic Stem Cells in Defined Media. presented in 2010 world stem cell summit

    Induction of Pluripotency of hESC and iPSC

  1. X. Gao et. al. Comparative transcriptomic analysis of endothelial progenitor cells derived fro umbilical cord blood and adult peripheral blood: Implications for the generation of induced pluripotent stem cells. Stem Cell Research, 2017
  2. M.V. Krivega et al. Cyclin E1 plays a key role in balancing between totipotency and differentiation in human embryonic cells. Mol. Hum. Reprod, 2015
  3. S. Herz, Optimization of RNA-based transgene expression by targeting Protein Kinase R. Dissertation for the degree “Doctor rerum naturalium”, 2015
  4. S. Eminli-Meissner et al. A novel four transfection protocol for deriving iPS cell lines fro human blood- derivedendothelial progenitor cells (EPCs) and adult human dermal fibroblasts using a cocktail of non-modified reprogrammingand immune evasion mRNAs. Sientific Poster, REPROCELL, 2015
  5. M. Brouwer et al. Choices for Induction of Pluripotency: Recent Developments in Human Induced Pluripotent StemCell Reprogramming Strategies. Stem Cell Reviews and Reports: Volume 12, Issue 1, pp 54–72, 2015
  6. R. S. Song et al. Generation, Expansion, and Differentiation of Human Induced Pluripotent Stem Cells (hiPSCs) Derived fro the Umbilical Cords of Newborns. Current protocols in stem cell biology (2013): UNIT 1C.16.
  7. Warren, L., et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7: 618-630, 2010
  8. S. Sugii et al., Human and mouse adipose-derived cells support feeder-independent induction of pluripotent stem cells. PNAS February 23, 2010 vol. 107 no. 8 3558-3563


  9. Proteins and Antibodies Expression and Isolation

  10. D.R. Riordon and K.R. Boheler, Immunophenotyping of Live Human Pluripotent Stem Cells by Flow Cytometry. In: Boheler K., Gundry R. (eds) The Surfaceome. Methods in Molecular Biology, vol 1722. Humana Press, New York, NY, 2018
  11. N.Y. Thakar et al., TRAF2 recruitment via T61 in CD30 drives NFkB activation and enhances hESC survival andproliferation, Molecular Biology of the Cell: 26(5):993-1006 2015
  12. Abcam, Immunocytochemistry / Immunofluorescence abreview for Anti-Oct4 antibody - ChIP Grade. Abcam website


  13. Clinical Applications- Derivation and Expansion of hESC and IPSC

  14. L. de Oñate et al. 2015. Research on Skeletal Muscle Diseases Using Pluripotent Stem Cells. DOI: 10.5772/60902
  15. P. Menasché et al., Towards a Clinical Use of Human Embryonic Stem Cell-Derived Cardiac Progenitors:A Translational Experience. European Heart Journal: Volume 36, Issue 12, pp 743-50, 2015
  16. P. Menasché et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. European heart journal (2015): ehv189.
  17. T. Seki, K. Fukuda, Methods of induced pluripotent stem cells for clinical application, World Journal of Stem Cells: Volume 7, Issue 1, pp 116–125, 2015
  18. Y. Luo et al.,Stable Enhanced Green Fluorescent Protein Expression After Differentiation and Transplantation of Reporter Human Induced Pluripotent Stem Cells Generated by AAVS1 Transcription Activator-Like Effector Nucleases, STEM CELLS Translational Medicine: Volume 3, Issue 7, pp 821-35, 2014
  19. J. Durruthy-Durruthy et al. Rapid and Efficient Conversion of Integration-Free Human Induced Pluripotent Stem Cells to GMP-Grade Culture Conditions. PlOS one: http://dx.doi.org/10.1371/journal.pone.0094231, 2014
  20. H. Tateno et al. A medium hyperglycosylated podocalyxin enables noninvasive and quantitative detection of tumorigenic human pluripotent stem cells. Scientific Reports 4, Article number: 4069, 2014
  21. S. Abbasalizadeh, H. Baharvand. Technologies progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies. Biotechnology Advances: Volume 31, Issue 8, pp 1600-23, 2013.
  22. J. P. Awe et al. Generation and characterization of transgene-free human induced pluripotent stem cells and conversion to putative clinical-grade status. Stem Cell Research & Therapy, 2013, 4:87
  23. O. Hovatta. Infectious problems associated with transplantation of cells differentiated fro pluripotent stem cells. Seminars in Immunopathology: Volume 33, Issue 6, pp 627-30, April 2011
  24. S. Ström. Optimisation of human embryonic stem cell derivation and culture – towards clinical quality. Karolinska Institutet, Stockholm, Sweden, 2010


  25. Drug Screening

  26. Z. Ye et al., Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoieticprogenitors


  27. Animal Models

  28. W. Zhang, et al. Distinct MicroRNA Expression Signatures of Porcine Induced Pluripotent Stem Cells under Mouse and Human ESC Culture Conditions. PLOS ONE, 2016


  29. Patents

  30. J. Mata-fink et al. Methods and Compositions For Immunomodulation. US Patent Application 20170020926, 2017
  31. Bailly, J., et al. Method for differentiation of pluripotent stem cells into multi-competent renal precursors. US Patent 20,160,145,578, 2016
  32. K. Tryggvason et al. Differentiation of pluripotent stem cells and cardiac progenitor cells into striated cardiomyocyte fibers using laminins LN-511, LN-521 and LN-221. US Patent Application 20160122717, 2016
  33. D. Keefe et al. A Method for a Single Cell Analysis of Telomere Length. US Patent Application 20160032360, 2016
  34. Dietrich M. EGLI, Methods for making and using modified oocytes . US Patent Application 20140308257, 2016
  35. M. Mikkola et. al. A Method for Generating Induced Pluripotent Stem Cells. US Patent Application 20160068818, 2016
  36. H Tateno et al. Undifferentiated Cell Detection Method and Complex Carbohydrate Detection Method. US Patent Application 20150204870, 2015
  37. O. Hovatta, K. Tryggvason, Methods of Producing RPE Cells. US Patent Application 20150299653, 2015
  38. A. De Fougerolles, S.M. Elbashir, Delivery and Formulation of Engineered Nucleic Acids, US Patent Application 20150017211, 2015
  39. Sahin, U., et al. Diagnosis and therapy of cancer involving cancer stem cells. US Patent Application 20150314018, 2015
  40. U. Sahin et al. Method for Cellular RNA Expression. US Patent Application 20150314018, 2015
  41. M.F Yanik, M. Angel. Methods for Transfecting Cells With Nucleic Acids. US Patent Application 20140073053, 2014
  42. C.E Buensuceso et al., Induced Pluripotent Stem Cells Prepared fro Human Kidney-Derived Cells. US Patent Application 20140073049, 2014
  43. C. Buensuceso et al., Induced Pluripotent Stem Cells fro Human Umbilical Cord Tissue-Derived Cells. US Patent Application 20130157365, 2013
  44. A. De Fougerolles, S.M. Elbashir, J.P. Schrum. Modified Polynucleotided for the Production of Factor IX. US Patent Application 20130245103, 2013
  45. M. Amit, J. Itskovitz-eldor. Novel Methods and Culture Media for Culturing Pluripotent Stem Cells. US Patent Application 20130236961, 2013
  46. E. Zambidis, P Burridge. Compositions and Methods of Generating a Differentiated Mesodermal Cell. US Patent Application 20130136721, 2013.

Documentation

Reviews

Customer Reviews (1)

Five Stars, highly recommendedReview by John
Quality
Worked very well for us. High quality medium that gave us the most control over our cells. Ingredients you need. Highly recommended. (Posted on 10/24/2017)

Write Your Own Review

You're reviewing: NutriStem® hPSC XF Medium

How do you rate this product? *

  1 star 2 stars 3 stars 4 stars 5 stars
Quality

Tags

Tags

Other people marked this product with these tags:

Use spaces to separate tags. Use single quotes (') for phrases.

You may also be interested in the following product(s)